Boston Scientific (BSX) Announces CE Mark Approval for COGNIS

Article Stock Quotes (1) Comments (0)

Boston Scientific Corporation (NYSE: BSX) announced CE Mark approval for its COGNIS cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN implantable cardioverter defibrillator (ICD). These devices represent entirely new platforms to treat heart failure and sudden cardiac death and are the result of a multi-year research and development effort to provide physicians enhanced clinical options for their patients.

You May Also Be Interested In

• Boston Scientific (BSX) Reports Positive Results from NG PROMUS, EVOLVE
• Boston Scientific Reports Lotus™ Valve System Met Primary Performance Endpoint in REPRISE II Trial
• Merck's (MRK) Suvorexant Helps People Sleep, Says FDA

Create E-mail Alert Related Categories

FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?